Baseline Extracellular HMGB-1 Levels Associated with Induction Chemotherapy Response in Adult Acute Myeloid Leukemia
F1000Research · 2026
DOI: 10.12688/f1000research.183970.2 ↗Kurz gefasst
Fachartikel in der Zeitschrift F1000Research, 2026. Verfasst von Resti Mulya Sari und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Medical Oncology, Dharmais Cancer Hospital, Jakarta, Indonesia. Hauptthemen laut MEDLINE: HMGB1 Protein, Leukemia, Myeloid, Acute, Induction Chemotherapy, Biomarkers, Tumor. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Clinical Research Unit of National Cancer Center – Dharmais Cancer Hospital.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Treatment response in acute myeloid leukemia (AML) is influenced by multiple biological and molecular mechanisms. High-mobility group box 1 (HMGB-1) is involved in inflammation, autophagy, apoptosis, and immunogenic cell death. This study evaluated associations of baseline circulating miR-181a-3p, miR-181b-5p, ATM, ATR, and HMGB-1 with successful induction response in adults with newly diagnosed AML.
Methods
This prospective cohort study was conducted at two referral hospitals in Jakarta, Indonesia. Adults with newly diagnosed AML receiving standard D3A7 induction chemotherapy were enrolled consecutively. Baseline miR-181a-3p and miR-181b-5p were quantified using digital polymerase chain reaction, whereas ATM, ATR, and HMGB-1 were measured using enzyme-linked immunosorbent assays before chemotherapy. Successful induction response was assessed by clinical and bone marrow evaluation after induction. Receiver operating characteristic analysis determined an exploratory HMGB-1 cut-off. Associations were evaluated using relative risks (RRs) with 95% confidence intervals (CIs).
Results
Among 102 patients initiating induction chemotherapy, 25 died during induction or early post-induction care. The biomarker-evaluable cohort comprised 71 patients, of whom 40 (56.3%) achieved a successful response. Baseline miR-181a-3p, miR-181b-5p, ATM, and ATR were not significantly associated with response. HMGB-1 yielded an area under the curve of 0.615 (95% CI, 0.480–0.749). The exploratory cut-off was 28.59 pg/mL, with 65.0% sensitivity and 61.3% specificity. Low HMGB-1 was associated with a lower probability of successful response (RR, 0.620; 95% CI, 0.394–0.975; p = 0.038). In the final clinical-biomolecular model, high HMGB-1 remained associated with successful response after adjustment for platelet count and ATR (adjusted RR, 1.666; 95% CI, 1.092–2.541; p = 0.018).
Conclusion
Low baseline circulating HMGB-1 was associated with a lower probability of successful induction response in the biomarker-evaluable adult AML cohort. Given its modest discriminatory performance and internally derived cut-off, HMGB-1 should be considered an exploratory complementary biomarker requiring external validation and serial evaluation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology and Medical Oncology, Dharmais Cancer Hospital, Jakarta, Indonesia.
- Department of Hematology and Cellular Therapy, Dharmais Cancer Hospital, Jakarta, Indonesia.
- Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Diponegoro University, Semarang, Indonesia.
- Department of Pharmacology and Therapeutics, Faculty of Medicine, Indonesia University, Jakarta, Indonesia.
- Department of Biochemistry and Molecular Biology, Faculty of Medicine, Indonesia University, Jakarta, Indonesia.
- Division of Hematology and Medical Oncology, Cipto Mangunkusumo National General Hospital, Faculty of Medicine, Indonesia University, Jakarta, Indonesia.
ORCID-Profile: Resti Mulya Sari, Lyana Setiawan, Ikhwan Rinaldi
Förderung
- The Clinical Research Unit of National Cancer Center – Dharmais Cancer Hospital
Zitieren
APA
Mulya Sari, R., Setiawan, L., Santosa, D., Dewi, S., Louisa, M., Rinaldi, I., & Sutandyo, N. (2026). Baseline Extracellular HMGB-1 Levels Associated with Induction Chemotherapy Response in Adult Acute Myeloid Leukemia. F1000Research. https://doi.org/10.12688/f1000research.183970.2
Vancouver
Mulya Sari R, Setiawan L, Santosa D, Dewi S, Louisa M, Rinaldi I, et al. Baseline Extracellular HMGB-1 Levels Associated with Induction Chemotherapy Response in Adult Acute Myeloid Leukemia. F1000Research. 2026. doi:10.12688/f1000research.183970.2
BibTeX
@article{MulyaSari2026,
author = {Mulya Sari, Resti and Setiawan, Lyana and Santosa, Damai and Dewi, Syarifah and Louisa, Melva and Rinaldi, Ikhwan and Sutandyo, Noorwati},
title = {Baseline Extracellular HMGB-1 Levels Associated with Induction Chemotherapy Response in Adult Acute Myeloid Leukemia},
journal = {F1000Research},
year = {2026},
doi = {10.12688/f1000research.183970.2}
}
EUVIMED